Ipca Laboratories Limited (IPCALAB)

Name: Ipca Laboratories Limited (IPCALAB) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-09-20

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas.

Cifras clave

Capitalización bursátil: ₹510 billion
Ingresos (ejercicio cerrado en 2026-03-31): ₹95.6B
Beneficio neto: ₹11.4B
Margen bruto: 68.8%
Margen neto: 11.9%

Ver gráficos interactivos y estados completos →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Ingresos totales	₹95.6B	₹88.5B	₹76.2B	₹62.1B	—
Beneficio bruto	₹65.8B	₹59.2B	₹49.0B	₹38.0B	—
Ingresos operativos (EBIT)	₹16.3B	₹13.6B	₹9.3B	₹7.0B	—
Ingresos netos	₹11.4B	₹7.4B	₹5.5B	₹4.7B	—

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de IPCALAB. /companies/us/IPCALAB

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.